Invests in
Sectors:
Min Investment:
$5,000,000.00Max Investment:
$25,000,000.00Target Investment:
$15,000,000.00
Skills
Education
- Uo
- HS
Lists including Jason
Investments
Work Experience
2021
General Partner
2023
Partner
2021 - 2023
DCVC backs brilliant entrepreneurs applying Deep Tech, from the earliest stage and beyond, to pragmatically and cost-effectively tackle previously unsolvable problems in nearly every industry.
2025
Board Member
2025
Dayhoff Labs builds foundational AI for chemistry and biochemistry to solve deep challenges in both, ranging from catalysis and green synthesis to ab initio synthetic biology.
2023
Board Chair
2023
Kanvas's novel spatial biology platform enables an unprecedented understanding of host-microbiome interaction and provides an efficient approach to drug discovery for live biological products.
2023
Board Member
2023
Recycleye sells AI robotics and computer vision technologies for innovative waste and materials management.
2023
Board Member
2023
Aquafortus was founded in New Zealand to develop and commercialize a novel and proprietary zero liquid discharge technology that can treat high salinity wastewater at a fraction of the cost of current processes.
2022
Board Member
2022
Relation is pioneering a “Lab-in-the-Loop” that can integrate active learning at every step of drug discovery, from predicting cell states to the validation of new targets.
2022
Board Chair
2022
ZwitterCo's zwitterionic membranes can handle unprecedented levels of oil and grease without irreversible fouling, recovering full performance.
2021
Board Member
2021
Evonetix is reimagining biology by developing a radically different approach to gene synthesis – a highly parallel desktop platform to synthesize DNA at unprecedented accuracy, scale and speed. The company's platform will place DNA synthesis in the hands of every researcher and change how DNA is accessed, made, and used—a new paradigm for gene synthesis.
2019
Founding Board Member, Cofounder, and Initial Investor (through Social Impact Capital)
2019
Applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.
2018
Contributing Writer
2018
I write a column twice a month for Wired's IDEAS vertical and contribute occasional features to Wired magazine.